AMACR Antikörper

Produktnummer ABIN968957

Der Maus Monoklonal Anti-AMACR-Antikörper wurde für WB, IHC, ELISA und ICC validiert. Er ist geeignet, AMACR in Proben von Human und Maus zu detektieren. Es sind 2+ Publikationen verfügbar.

Kurzübersicht für AMACR Antikörper (ABIN968957)

Target: AMACR (alpha-Methylacyl-CoA Racemase (AMACR))

Reaktivität: Human, Maus

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser AMACR Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Immunocytochemistry (ICC)

Klon: 2A10F3

Produktdetails anti-AMACR Antikörper

Verwendungszweck: AMACR Antibody

Aufreinigung: Ascitic fluid

Immunogen: Purified recombinant fragment of human AMACR expressed in E. Coli.

Isotyp: IgG2b

Anwendungsinformationen

Applikationshinweise:

ELISA: 1/10000

ICC: 1/200 - 1/1000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Referenzen für anti-AMACR Antikörper (ABIN968957)

Chen, Watson, Marengo, Decker, Coleman, Nelson, Sikes: "Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo." in: Cancer letters, Vol. 244, Issue 2, pp. 274-88, (2006) (PubMed).

Epstein, Herawi: "Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care." in: The Journal of urology, Vol. 175, Issue 3 Pt 1, pp. 820-34, (2006) (PubMed).

Details zu AMACR

Target: AMACR (alpha-Methylacyl-CoA Racemase (AMACR))

Andere Bezeichnung: AMACR

Hintergrund: AMACR (alpha-methylacyl-CoA racemase) has been recently described as prostate cancer-specific gene that encodes a protein involved in the beta-oxidation of branched chain fatty acids. Expression of AMACR protein is found in prostatic adenocarcinoma but not in benign prostatic tissue. It stains premalignant lesions of prostate: high-grade prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia. AMACR can be used as a positive marker for PIN. Defects in AMACR are the cause of congenital bile acid synthesis defect type 4 (CBAS4), also known as cholestasis, intrahepatic, with defective conversion of trihydroxycoprostanic acid to cholic acid or trihydroxycoprostanic acid in bile. Clinical features include neonatal jaundice, intrahepatic cholestasis, bile duct deficiency and absence of cholic acid from bile.

Molekulargewicht: 42 kDa

UniProt: Q9UHK6

Pathways: Monocarboxylic Acid Catabolic Process